IMO, RVX and Zenith should be packaged up together for $1 Billion USD, there are several pharma already at the table with Zenith in clinical collaboration deals so why not take it all for the cheap, With the BTD in place at RVX  , Pharma's could easily run with the trials quickly and start generating revenue from both Apabetalone and Zen 3694, $ 1 Billion would be cheap based on future revenue generation . Wth RVX  Tax losses of up to $400 Million can be used against future profits on reveune  , it seems like a no brainer for BP to get a hold of all the IP.   God knows RVX management can't get the trials done on their own.  I doubt this silence has anything to do with any pending deals.  I hope I am wrong, as I ahve been many many times.....